HER2/EGFR in Cancer Research

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the use of HER2-targeted therapies, such as trastuzumab and pertuzumab, in the treatment of HER2-positive breast cancer. It explores the mechanisms of action, resistance, and combination therapies involving chemotherapy and monoclonal antibodies. The cluster also delves into the role of EGFR, neuregulin 1, and ADAM metalloproteinases in HER2 signaling and breast cancer progression.

352

Works

IDs:OpenAlex

How has HER2/EGFR in Cancer Research's publication output changed over time?

ScholarIQpublication output · 2001–2023

Output grew0% over the shown period — from 1 works in 2001 to 1 in 2023.

2001200520072010201120182019202120222023

What are the most-cited papers on HER2/EGFR in Cancer Research?

ScholarIQmost cited works

Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2

Dennis J. Slamon, Brian Leyland‐Jones, Steven Shak, H. Fuchs, Virginia Paton, Alex Bajamonde, Thomas Fleming, W. Eiermann, Janet Wolter, Mark D. Pegram, José Baselga, Larry Norton

New England Journal of Medicine. 200111,555 CitationsOPEN ACCESS

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

Edward H. Romond, Edith A. Perez, John Bryant, Vera J. Suman, Charles E. Geyer, Nancy E. Davidson, Elizabeth Tan-Chiu, Silvana Martino, Soonmyung Paik, Peter A. Kaufman, Sandra M. Swain, Thomas M. Pisansky, Louis Fehrenbacher, Leila A. Kutteh, Victor G. Vogel, Daniel W. Visscher, Greg Yothers, Robert B. Jenkins, Ann Brown, Shaker R. Dakhil, Eleftherios P. Mamounas, Wilma L. Lingle, Pamela Klein, James N. Ingle, Norman Wolmark

New England Journal of Medicine. 20055,365 CitationsOPEN ACCESS

Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer

Martine Piccart, Marion Procter, Brian Leyland‐Jones, Aron Goldhirsch, Michael Untch, Ian Smith, Luca Gianni, José Baselga, Richard H. Bell, Christian Jackisch, David Cameron, Mitch Dowsett, Carlos H. Barrios, Günther Steger, Chiun‐Sheng Huang, Michael Andersson, Moshe Inbar, Mikhail Lichinitser, István Láng, Ulrike Nitz, Hiroji Iwata, Christoph Thomssen, Caroline Lohrisch, Thomas Suter, Josef Rüschoff, Tamás Sütö, Victoria Greatorex, Carol Ward, Carolyn Straehle, Eleanor McFadden, Mirko Dolci, Richard D. Gelber

New England Journal of Medicine. 20055,111 CitationsOPEN ACCESS

Adjuvant Trastuzumab in HER2-Positive Breast Cancer

Dennis J. Slamon, W. Eiermann, Nicholas J. Robert, Tadeusz Pieńkowski, Miguel Martín, Michael F. Press, John R. Mackey, John A. Glaspy, Arlene Chan, Marek Pawlicki, Tamás Pintér, Vicente Valero, Mei-Ching Liu, Guido Sauter, Gϋnter von Minckwitz, F. Visco, Valerie Bée, Marc Buyse, Belguendouz Bendahmane, Isabelle Tabah-Fisch, Mary-Ann Lindsay, A. Riva, John Crown

New England Journal of Medicine. 20112,784 CitationsOPEN ACCESS

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gϋnter von Minckwitz, Chiun‐Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiß, Andrés Redondo, Hans Holger Fischer, William Jacot, Alison Conlin, Claudia Arce-Salinas, Irene Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John Crown, P Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie C. Smitt, Hannah Douthwaite, Stina Mui Singel, Charles E. Geyer

New England Journal of Medicine. 20182,652 CitationsOPEN ACCESS